SpectaCell raises €6 million Seed round to bring better treatments to patients faster

Immunotherapies are redefining the future of medicine, opening new ways to treat cancer and diseases of the immune system. But predicting which treatments will work remains a major challenge.

SpectaCell is developing a new cell analysis platform that shows how individual cells respond to potential treatments. It enables researchers to compare drug candidates and helps them decide which treatment to pursue.

The company - the first spin-off from a long-standing research collaboration between imec, VIB and Ghent University - has raised €6 million in Seed funding to further develop and commercialize its technology.

“Breakthrough medicines need breakthrough tools. Researchers need to know much earlier which candidates deserve further investment and why. We are building a new standard in cell analysis: detailed insight, results within hours and a simple workflow that connects research with manufacturing. Together with our biopharma partners, we will turn that vision into a platform for developing better treatments more efficiently. And ultimately, that is what we want to make possible for patients: better medicines, sooner.”

Tony Montoye
CEO and co-founder of SpectaCell

“SpectaCell brings together disruptive semiconductor technology, an experienced team and a major commercial opportunity in drug development and manufacturing. We are convinced that SpectaCell can become essential to how new medicines are selected, developed and produced. With applications across cell therapies, T-cell engagers and other advanced treatments, we see the potential to set a new industry standard and build a globally competitive life-sciences business. We are proud to lead this round and back that ambition.”

Benoit Devogelaere
Partner at imec.xpand

You can read the full press release on the SpectaCell website: www.spectacell.com/news